BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Brussels – Belgian specialist for regenerative medicine TiGenix NV has raised EUR15.2m through the sale of 15.2 million shares at EUR1/share in a rights issue. Existing shareholders, who were eligible to purchase one share for...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Mechelen – Belgian drug discovery specialist Galapagos NV has sold its compound business to competitor Evotec AG. The German drug-discovery services specialist thereby acquires the affiliate Compound Focus Inc., which is key to...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Amsterdam – European life sciences investor Life Sciences Partners (LSP) has raised EUR36m in an IPO for its first in-house fund to invest in public companies, selling 360,000 shares at EUR100/share. New shares in the fund, which...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

One or zero, black or white, top or flop – digital results. Few sectors test the nerves of entrepreneurs, employees, partners and investors quite as much as biotechnology. Even if you have plenty of expertise, forecasting the...

BeNeLuxBelgiumNetherlandsLuxembourg

07.06.2011

Amsterdam – US-Dutch MolDx company Agendia N.V. has announced details of its planned IPO on NYSE Euronext in Amsterdam. The developer of microarray-based predictive diagnostics said it will issue 4,587,156 ordinary shares worth...

BeNeLuxBelgiumNetherlandsLuxembourg

31.05.2011

Amsterdam – Two studies presented at the annual conference of the European Society of Human Genetics yesterday show that common Direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and thus European...

BeNeLuxBelgiumNetherlandsLuxembourg

23.05.2011

Leuven – Genetically engineered poplars with less lignin grown in a field trial in Belgium deliver 81% more bio-ethanol than non-modified poplars when enzymatically digested and fermented, according to Belgian researchers headed...

BeNeLuxBelgiumNetherlandsLuxembourg

18.04.2011

Mechelen – Belgian Galapagos NV has terminated a Phase 2 study forGLP0259 in rheumatoid arthritis after an interim analysis showed the drug was not efficient. The failure affects Galapagos’ research agreement with Janssen...

BeNeLuxBelgiumNetherlandsLuxembourg

08.04.2011

Eindhoven – Researchers from Dutch imaging specialist Philips Electronics and the Eindhoven University of Technology have developed a technique that could help boost efficacy and at the same time reduce the side effects of...

BeNeLuxBelgiumNetherlandsLuxembourg

06.04.2011

Leuven – Belgian biotech TiGenix NV has agreed to merge operations with Spain-based Cellerix and raise a15m in a rights issue to expand further into regenerative medicine. TiGenix said it had agreed to combine operations though a...

Displaying results 41 to 50 out of 304

< Previous 41-50 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/4/article/actogenix-20-million-euros-round.html

Whitepaper

Video

All videos

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%

FLOP

  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%

FLOP

  • BIOTEST (D)27.24 EUR-60.8%
  • BIOTECH PHARMACON (N)9.43 NOK-46.1%
  • TRANSGENE (F)2.80 EUR-23.9%

TOP

  • ADOCIA (F)88.74 EUR587.4%
  • DBV TECHNOLOGIES (F)81.03 EUR328.7%
  • FORMYCON (D)28.70 EUR315.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.70 SEK-71.6%
  • NEOVACS (F)1.01 EUR-69.5%

No liability assumed, Date: 03.08.2015

Current issue

All issues